Options activity in a pharmaceutical stock has surged after its acquisition by Eli Lilly. Traders are closely watching the stock's performance amid the buyout.
- Options traders are increasing activity in a pharma stock post-buyout.
- The event is specific to the pharmaceutical sector.
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.
Share this article